Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on December 6, 2019 it closed the previously announced underwritten public offering of 4,600,000 shares of its common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 600,000 additional shares. The offering was priced at $58.00 per share, and the company received gross proceeds of $266.8 million, before deducting underwriting discounts, commissions and other offering expenses payable by the company.

Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million

Pasadena, CA | Posted on December 7th, 2019

Goldman Sachs & Co. LLC, Jefferies LLC and Piper Jaffray & Co. are acting as bookrunning managers for the offering, Cantor Fitzgerald & Co. is acting as passive joint bookrunner for the offering and Robert W. Baird & Co. Incorporated and B. Riley FBR, Inc. are acting as co-managers for the offering. Arrowhead intends to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, research and development expenditures and clinical trial expenditures. A portion of the net proceeds may also be used for the acquisition of complementary businesses, products and technologies, or for other strategic purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

####

About Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference, or RNAi, mechanism to induce rapid, deep, and durable knockdown of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding our expectations with respect to the use of proceeds from Arrowhead’s public offering. These statements are based upon our current expectations and speak only as of the date hereof. Arrowhead’s actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, without limitation, risks and uncertainties associated with market conditions. Arrowhead’s most recent Annual Report on Form 10-K and other filings Arrowhead makes with the SEC from time to time discuss some of the important risk factors that may affect its ability to achieve the anticipated results, as well as Arrowhead’s business, results of operations and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements. Additionally, Arrowhead disclaims any intent to update these forward-looking statements to reflect subsequent developments.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Let the europium shine brighter January 21st, 2020

Nanotubes may give the world better batteries: Rice U. scientists' method quenches lithium metal dendrites in batteries that charge faster, last longer January 16th, 2020

Quantum physics: Controlled experiment observes self-organized criticality January 16th, 2020

Pretty with a twist: Complex porous, chiral nano-patterns arise from a simple linear building block January 16th, 2020

Investments/IPO's/Splits

Onto Innovation to Present at the 22nd Annual Needham Growth Conference January 3rd, 2020

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock December 5th, 2019

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock December 3rd, 2019

Onto Innovation to Participate in the 8th Annual NYC Investor Summit 2019 November 21st, 2019

Nanomedicine

Nanomaterial fabric destroys nerve agents in battlefield-relevant conditions: Metal-organic framework-based composites don’t need liquid water to work January 14th, 2020

A New Old Therapy: A controlled phage therapy can target drug-resistant bacteria while sidestepping potential unintended consequences January 13th, 2020

Copper-based nanomaterials can kill cancer cells in mice January 10th, 2020

Molecular factories: The combination between nature and chemistry is functional January 10th, 2020

Announcements

Let the europium shine brighter January 21st, 2020

Quantum physics: Controlled experiment observes self-organized criticality January 16th, 2020

Pretty with a twist: Complex porous, chiral nano-patterns arise from a simple linear building block January 16th, 2020

Toward safer disposal of printed circuit boards January 16th, 2020

Nanobiotechnology

Pretty with a twist: Complex porous, chiral nano-patterns arise from a simple linear building block January 16th, 2020

A New Old Therapy: A controlled phage therapy can target drug-resistant bacteria while sidestepping potential unintended consequences January 13th, 2020

Copper-based nanomaterials can kill cancer cells in mice January 10th, 2020

Molecular factories: The combination between nature and chemistry is functional January 10th, 2020

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project